Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors-Reference-Cited by-同舟云学术

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Published:2017-11-21 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Dembla Vikas,Groisberg Roman,Hess Ken,Fu Siqing,Wheler Jennifer,Hong David S.,Janku Filip,Zinner Ralph,Piha-Paul Sarina Anne,Ravi Vinod,Benjamin Robert S.,Patel Shreyaskumar,Somaiah Neeta,Herzog Cynthia E.,Karp Daniel D.,Roszik Jason^ORCID,Meric-Bernstam Funda,Subbiah Vivek^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-13114-8.pdf

Reference23 articles.

1. van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879–1886, https://doi.org/10.1016/S0140-6736(12)60651-5 (2012).

2. Mohindra, N. & Agulnik, M. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas. Expert opinion on investigational drugs 24, 1409–1418, https://doi.org/10.1517/13543784.2015.1076792 (2015).

3. Munhoz, R. R. et al. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. The oncologist 20, 1245–1246, https://doi.org/10.1634/theoncologist.2015-0245 (2015).

4. Porta, C. et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert review of anticancer therapy 12, 1571–1577, https://doi.org/10.1586/era.12.81 (2012).

5. Gossage, L. & Eisen, T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 16, 1973–1978, https://doi.org/10.1158/1078-0432.ccr-09-3182 (2010).

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future directions of systemic therapy in high-grade bone sarcomas;N.N. Priorov Journal of Traumatology and Orthopedics;2024-07-04

2. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma;Frontiers in Oncology;2023-03-13

3. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102);Clinical Cancer Research;2022-10-26

4. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer;Pharmaceuticals;2022-05-26

5. Tyrosine kinase inhibitors in sarcoma treatment (Review);Oncology Letters;2022-04-21